Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenas BioPharmaZBIO -3.83%8 Market Cap is $2,028.30 Mil as of Sep. 11, 2026. GuruFocus rates ZBIO with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, Zenas BioPharma ranks better than 88.53% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zenas BioPharma's share price for the quarter that ended in Jun. 2026 was $25.38. Zenas BioPharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 63.33 Mil. Therefore, Zenas BioPharma's market cap for the quarter that ended in Jun. 2026 was $1,607.34 Mil.
Zenas BioPharma's quarterly market cap
declined
from Dec. 2025 ($1,978.39 Mil) to Mar. 2026 ($1,219.59 Mil) but then
increased
from Mar. 2026 ($1,219.59 Mil) to Jun. 2026 ($1,607.34 Mil).
Zenas BioPharma's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($342.28 Mil) and
increased
from Dec. 2024 ($342.28 Mil) to Dec. 2025 ($1,978.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zenas BioPharma's Enterprise Value for Today is $1,683.04 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zenas BioPharma Market Cap Related Terms
Zenas BioPharma Market Cap Historical Data
* Premium members only.
The historical data trend for Zenas BioPharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zenas BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenas BioPharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Zenas BioPharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zenas BioPharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenas BioPharma (ZBIO) has a Market Cap of $2,028.30 Mil as of Sep. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zenas BioPharma and its competitors. According to the industry distribution chart, Zenas BioPharma ranks #163 out of 1421 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Zenas BioPharma's Market Cap too high?
Zenas BioPharma's current Market Cap is $2,028.30 Mil. The Biotechnology industry median Market Cap is 118.46. Zenas BioPharma's value of $2,028.30 Mil is 1612.2% above this industry median. Based on the distribution chart, Zenas BioPharma ranks #163 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zenas BioPharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Market Cap compare to STOK and ZYME?
According to the Biotechnology industry distribution chart, Zenas BioPharma ranks #163 out of 1421 companies for Market Cap. This places Zenas BioPharma in the top 12% of its industry — outperforming the majority of peers. The industry median Market Cap is 118.46. Zenas BioPharma's value of $2,028.30 Mil is 1612.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.46, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenas BioPharma's current Market Cap of $2,028.30 Mil is 1612.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zenas BioPharma and its competitors. For the Biotechnology industry, the median Market Cap is 118.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenas BioPharma's current Market Cap is $2,028.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Market Cap of $2,028.30 Mil. The current Market Cap is $2,028.30 Mil and 1612.2% above the Biotechnology industry median of 118.46. Zenas BioPharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Market Cap is $2,028.30 Mil as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
8GF Score
Get the complete analysis for ZBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZBIO has been successfully added to your 
